Tasigna

PreclinicalSmall molecule

Novartis

Tasigna is one of 18 small molecule programs targeting Chronic Myelogenous Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Myelogenous LeukemiaUnknown

Chronic Myelogenous LeukemiaPreclinical

Unknown

Competition

Competitive Landscape

17 competitors in Chronic Myelogenous Leukemia

#DrugCompanyPhaseTrials

Gleevec

Novartis

Approved

39 2

Tasigna

AAzurity Pharmaceuticals

Approved

17 3

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

12 4

Bosulif

PPrism Pharmaceuticals

Approved

5 5

Tukysa

Depakote

Jakafi

Scemblix

5 9

Nizoral

WWim Janssens

Approved

—10

Nerlynx

PPuma Biotechnology, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Plexiform Neurofibroma1 trial

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Completed·IIndiana University·Phase 1·NCT01275586·6 enrolled

Pregnancy1 trial

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

Completed· Novartis logo

Novartis··NCT01289054·4 enrolled

Adult1 trial

A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.

Completed·XXspray Pharma AB·Phase 1·NCT07138378·128 enrolled

MPA1 trial

Pharmacokinetic Comparison of XS003 and Tasigna

Completed·XXSpray Microparticles·Phase 1·NCT02068898·27 enrolled

Metabolism1 trial

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

Completed· Novartis logo

Novartis·Phase 1·NCT01223898·19 enrolled

1 more indication

Synovitis1 trial

Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)

Completed·CCentre Leon Berard·Phase 2·NCT01261429·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Tasigna. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tasigna compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tasigna. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novartis

Tasigna

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Plexiform Neurofibroma1 trial

Pregnancy1 trial

Adult1 trial

MPA1 trial

Metabolism1 trial

Synovitis1 trial

References

Drug Info

Quick Facts

Related News